Presenter: Mark Emalfarb, CEO
Market/Indication: Fungal based expression system speeds up the development and production of biologics
Funding Stage: Publicly Listed Ticker: NASDAQ: DYAI
Development Stage: Drug Discovery
Location: United States
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.